Abstract. Centromere protein F (CENPF) plays a key role in the regulation of the cell cycle. The present study revealed that CENPF was overexpressed in a variety of tumors and associated with the poor prognosis of osteosarcoma. The mRNA expression levels of CENPF were analyzed using the Gene Expression Profiling Interactive Analysis database and the protein levels of CENPF were detected in the specimens from patients with osteosarcoma using immunohistochemistry. Cell proliferation, cell cycle and flow cytometry assays were performed after the transfection of control or CENPF plasmids into osteosarcoma cells. A xenografts assay was used to determine the effects of CENPF on tumor growth in vivo. The results showed that CENPF was upregulated in osteosarcoma tissues and associated with high-grade tumor stage (P=0.023) and intraglandular dissemination (P=0.046). The transfection-induced depletion of CENPF in human osteosarcoma MG-63 and U-2 OS cell lines inhibited cell proliferation, stimulated apoptosis and induced cell cycle arrest. Induced CENPF depletion in MG-63 cells inhibited tumor growth of osteosarcoma cells in mice. These findings suggested that elevated CENPF levels contributed to increased cell proliferation by mediating apoptosis and cell cycle in osteosarcoma. Therefore, CENPF might be a potential biomarker for poor prognosis of osteosarcoma.

Introduction

Osteosarcoma is a type of primary malignant tumor that originates in the bones (1,2). Each year in the United States 800-900 new cases are diagnosed of which ~400 occur in children and adolescents under 20-years of age recent decades (3). Therefore, osteosarcoma has become the most common primary malignant bone tumor in children and adolescents (4). Due to the combination of surgery and chemotherapy, the survival rate of osteosarcoma has been significantly improved with a current overall expected cure rate of 50-65% (5).

Centromere protein F (CENPF) encodes a protein that binds with the centromere-kinetochore complex, and is located on the human chromosomal 1q41 (6). CENPF is a cell cycle-associated nuclear protein that is expressed at low levels during the G0/G1 phase and congregates in the nuclear matrix during S phase, with the highest expression in G2/M phase (7). CENPF protein has a broad expression in multiple tissues, such as the testis, bone marrow and lymph node (8). CENPF is also highly expressed in several types of human tumors, such as breast cancer, pancreatic carcinoma and prostate cancer and has been identified as a protein marker for tumor cell proliferation (9,10). To the best of our knowledge, the role of CENPF remains unclear in osteosarcoma. The aim of the present study was to investigate the relationship between CENPF expression and prognosis of patients with osteosarcoma.

Materials and methods

Patients and tissues. From January 2016 to December 2018, 67 patients with osteosarcoma from the Jiangxi Cancer Hospital (Jiangxi, China) were included in the present retrospective study. All patients had a complete medical history and underwent a physical pre-operative examination and primary tumor resection at hospital. The inclusion criteria were: i) Complete medical history; and ii) Physical pre-operative examination diagnosed by pathology. Patients who received preoperative radiotherapy or chemotherapy were excluded. The surgically removed tumor and adjacent normal tissue (5 mm distance from the tumor margin) was immediately fixed with 4% formalin at room temperature for 48 h and the diagnosis of osteosarcoma confirmed by two independent pathologists. The patients provided written consent for postoperative specimens to be used for scientific research before the operation. All experiments were approved by The Human Ethics Committee of Jiangxi Cancer Hospital.

Pathological evaluation. All clinical and clinicopathological characteristics were collected from the medical record of the
patients and the staging of tumors were performed according to The American Joint Committee on Cancer (11). The expression levels of CENPF in osteosarcoma were determined by two independent pathologists.

**Bioinformation analysis.** For the mRNA expression levels of CENPF in osteosarcoma, the boxplot and survival plots were plotted by the Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) database using data from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tdga). The specific parameters were as follows: Gene symbol=CENPF, ILog2FCI cut-off=1, P-value cut-off=0.01, log scale=yes, jitter size=0.4 and matched normal data=match TCGA normal data. For Kaplan-Meier survival plots, obtained from GEPIA (http://gepia.cancer-pku.cn/), the specific parameters were as follows: Methods=overall survival (OS) or disease-free survival (DFS), group cut-off=median, hazards ratio=yes, 95% confidence interval and axis units=months.

**IHC analysis.** The tumor tissues and adjacent tissues were cut into ~3-mm thick sections and fixed in 4% formalin for 24 h at room temperature. Subsequently, 4-µm sections were cut from the blocks, baked at 70°C for 30 min, dewaxed with dimethylbenzene for 30 min and rehydrated with a decreasing gradient series (100, 95, 85 and 75%) of ethanol for 30 min. To antigen retrieve, slides were heated in the citrate buffer at 100°C (pH 6.0) for 20 min in a microwave oven. To avoid interference with endogenous peroxidase, the slides were immersed in 3% hydrogen peroxide for 5 min at room temperature. Tissues were blocked using 10% goat serum (cat. no. E510009; BBI Life Sciences Corp.) for 20 min at room temperature, then incubated with anti-CENPF antibody (1:200 dilution; cat. no. ab224813; Abcam) at 4°C overnight. After washing with PBS three times, slides were incubated with horseradish peroxidase-labeled secondary antibody at room temperature for 30 min (1:1,000; goat anti-rabbit IgG; cat. no. ab6721; Abcam). Thereafter, slides were stained using 3,3-diaminobenzidine reagent for 2 min at room temperature, followed by counterstaining with hematoxylin for 1 min at room temperature. Finally, all sections were sealed with neutral balata and images were captured under a light microscope. The H-score system was used to evaluate the IHC score. Patients were divided into high (H-score ≥200) or low CENPF expression groups (H-score <200).

**Cell lines.** The human osteosarcoma cell lines MG-63 and U-2 OS were used in the present study. All cells were obtained from The Shanghai Institute of Biochemistry and Cell Biology. The MG-63 cells were maintained in DMEM (cat. no. 11965084; Thermo Fisher Scientific, Inc.) including wildtype and transfected MG-63 and U2-OS cells using TRIZol® reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.) and cDNA was synthesized using First Strand cDNA Synthesis kit (cat. no. K1621; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. ABI 7900HT QPCR Cycle and FastStart Universal SYBR® Green Master ( Rox (Roche Diagnostics). The following thermocycling conditions were used: 95°C for 5 min; 40 cycles of 95°C for 30 sec and 60°C for 1 min; and 60°C for 3 min. GAPDH was used for normalization and relative expression was calculated using the 2^−ΔΔCt method (12). The primer sequences used were as follows: GAPDH forward, 5'‑CAT CTC TGC CCC CTC TGC & Technology Co., Ltd.) and ImageJ software v1.8 (National Institutes of Health).

**Reverse transcription-quantitative (RT-q)PCR.** Total RNA was extracted from all cells, including wildtype and transfected MG-63 and U2-OS cells using TRizol® reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.) and cDNA was synthesized using First Strand cDNA Synthesis kit (cat. no. K1621; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Protein concentration was determined using the Bradford Protein Assay kit (cat. no. PC0010; Beijing Solarbio Science & Technology Co., Ltd.) was added to screen positive cells for 1 week and the drug concentration was maintained at all times.

**Immunoblotting.** All protein was obtained from cells, including wildtype and transfected MG-63 and U2-OS cells using RIPA buffer (cat. no. R0010; Beijing Solarbio Science & Technology Co., Ltd.) according to the manufacturer's protocol. Protein concentration was determined using the Bradford Protein Assay kit (cat. no. PC0010; Beijing Solarbio Science & Technology Co., Ltd.). Total protein (30 µg/lane) was separated by 10% SDS-PAGE, transferred onto a PVDF membrane, and blocked with 5% fat-free milk in TBST buffer (TBS buffer with 0.5% Tween-20) for 1 h at room temperature. Then, the membranes were incubated with anti-CENPF antibody (1:1,000 dilution; cat. no. ab224813; Abcam) overnight at 4°C. After washing with TBST buffer, the PVDF was incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5,000 dilution; cat. no. ab6721; Abcam) for 1 h at room temperature. Subsequently, the bands were visualized using an ECL kit (cat. no. 32132; Thermo Fisher Scientific, Inc.) and ImageJ software v1.8 (National Institutes of Health).

**Colonies formation assay.** MG-63 and U-2 OS cells were stably transfected with control or CENPF shRNA lentivirus, digested and seeded into six-well plates (10^5 cells/well) for 10 days. Then, cell colonies of cells were fixed with 4% paraformaldehyde for 30 min at 4°C and stained using crystal violet (0.2%)
for 30 min at room temperature. The number of cell colonies were counted using a light microscope (IX73; Olympus Corporation) and ImageJ software v.1.8.0 (National Institutes of Health).

**Cell Counting Kit (CCK)-8 assay.** To detect cell proliferation, osteosarcoma cells were seeded into 96-well plates in five replicates at a concentration of $10^3$ cells/well with 200 µl complete medium and incubated for 5 days. Cell proliferation was determined using CCK-8 reagent (cat. no. E606335; BBI Solutions). Simply, 20 µl of CCK-8 was added into each well, incubated for 2 h at 37˚C, and the absorbance was measured at 450 nm using a microplate reader.

**Flow cytometry assays.** Both cell cycle and apoptosis analysis were performed using a flow cytometer. For cell cycle assay, control and CENPF-knockdown cells were digested with 0.25% trypsin for 3 min at 37˚C and washed with PBS buffer. For cell cycle analysis, cells were fixed with 70% ethanol for 30 min at room temperature and stained with propidium iodide (PI; cat. no. 421301; BioLegend, Inc.) in the presence of RNase A and incubated for 20 min at room temperature. For the detection of early and late apoptosis, living cells were double stained with Annexin V-FITC and PI (CA1020; Beijing Solarbio Science & Technology Co., Ltd.) for 15 min at room temperature. Subsequently, osteosarcoma cells were analyzed using a flow cytometer (FC500; BD Biosciences) and FlowJo software v.7.6 (FlowJo LLC).

**Animal models.** A total of six female nude-BALB/c mice (seven-weeks-old, 18-22 g) were obtained from Chengdu Feike Biotechnology Co., Ltd. and maintained in a SPF environment with 12 h light/dark cycle, 22±2˚C and air humidity, 55±10%. All mice were provided with food and water ad libitum. Human endpoints were monitored every day, such as body weight loss of 20% and tumor diameter >20 mm. All mice were randomly divided into two groups: Subcutaneously inoculated with $10^6$ CENPF stably-depleted MG-63 cells. Tumor sizes were measured each 3 days. After 30 days, all mice were sacrificed and the tumors were isolated. Tumors were frozen immediately, followed by total protein extraction. The tumor volume was calculated using: $V = \frac{\text{Length} \times \text{width}^2}{2}$. The average tumor volume was 180 mm³. Euthanasia was performed using inipraperitoneal sodium pentobarbital 100 mg/kg injection. Euthanasia was confirmed by cervical dislocation. All experiments were approved by The Laboratory Animal Ethics Committee of Jiangxi Cancer Hospital (Jiangxi, China; approval. no. SYXK 2019-0522).

**Statistical analysis.** Data were derived from three independent biological replicates. Differences between two groups were tested using two-tailed, unpaired Student’s t-tests. The relationshps between CENPF and clinicopathological characteristics of 67 patients with osteosarcoma were analyzed using Pearson $\chi^2$ test or Yates continuity corrected $\chi^2$ test. The data was displayed by GraphPad Prism v5 (GraphPad Software, Inc.). Data are presented as mean ± standard deviation (unless otherwise shown). $P<0.05$ was considered to indicate a statistically significant difference.

**Results**

**High expression levels of CENPF mRNA are associated with poor OS and DFS rates in patients with osteosarcoma from the GEPIA database.** A total of 262 osteosarcoma tissues and two normal tissues from healthy patients without osteosarcoma were included from the GEPIA database and analyzed. The resultant expression boxplot demonstrated that CENPF was significantly overexpressed in osteosarcoma specimens at the mRNA level (Fig. 1A). The Kaplan-Meier showed that high expression levels of CENPF are associated with poor OS and DFS rates in patients with osteosarcoma (P=0.012 and 0.0033, respectively; Fig. 1B). These results indicated that CENPF was upregulated in osteosarcoma and associated with poor prognosis.
High expression levels of CENPF protein are associated with high T stage and intraglandular dissemination. A total of 67 patients with osteosarcoma were collected from 2016 to 2018. The protein expression levels of CENPF protein were evaluated using IHC, and the clinicopathological information of the patients was analyzed. As shown in the Fig. 2A-C, CENPF protein levels were significantly upregulated in osteosarcoma specimens compared with adjacent normal tissues. Performing clinicopathological characteristics analysis revealed that CENPF was upregulated in 82% (55 vs. 67) osteosarcoma specimens and high expression levels of CENPF protein were associated with T stage and intraglandular dissemination (Table I). These clinical data indicated high expression of CENPF was associated with poor prognosis in patients with osteosarcoma.

Depletion of CENPF in human osteosarcoma cell lines by CENPF shRNA transfection. To understand the functions of CENPF in osteosarcoma, CENPF was depleted by shRNA transfection in human osteosarcoma cell lines MG-63 and U-2 OS. As shown in Fig. 3A, the mRNA expression level of CENPF was significantly reduced in both cell lines after the stable transfection of CENPF shRNA plasmids. Similarly, immunoblotting showed that the protein expression levels of

### Table I. Relationships of CENPF and clinicopathological characteristics in 67 patients with osteosarcoma.

| Feature                      | Low, n=12 | High, n=55 | \( \chi^2 \) | P-value |
|------------------------------|-----------|------------|--------------|---------|
| Age, years                   |           |            |              |         |
| <45                          | 6         | 16         | 1.953        | 0.162   |
| ≥45                          | 6         | 39         |              |         |
| Sex                          |           |            |              |         |
| Male                         | 4         | 13         | 0.111        | 0.739   |
| Female                       | 8         | 42         |              |         |
| T stage                      |           |            |              |         |
| T1-T2                        | 8         | 15         | 5.146        | 0.023   |
| T3-T4                        | 4         | 40         |              |         |
| Lymph node metastasis        |           |            |              |         |
| Yes                          | 6         | 26         | 0.029        | 0.864   |
| No                           | 6         | 29         |              |         |
| Intraglandular dissemination |           |            |              |         |
| Yes                          | 4         | 38         | 3.965        | 0.046   |
| No                           | 8         | 17         |              |         |

CENPF, centromere protein F; T, tumor.
CENPF were decreased in shRNA stably transfected cells (Fig. 3B). Subsequent studies used CENPF-knockdown cell lines screened by puromycin.

**Depletion of CENPF inhibits cell proliferation by inducing cell cycle arrest at the G₁ phase.** Colony formation assays were performed to investigate whether CENPF affected osteosarcoma cell proliferation. As shown in Fig. 4A, the number of clones in CENPF-depleted cells was significantly decreased. In addition, the CCK-8 assays showed that the depletion of CENPF significantly decreased OD value, suggesting the inhibition of cell proliferation (Fig. 4B). To assess the effects of CENPF on apoptosis, control and CENPF-depleted cells were double-stained with Annexin V-FITC and PI. The flow cytometry assays revealed that knockdown of CENPF significantly induced apoptosis (Fig. 4C). Then, cell cycle assays also revealed that CENPF depletion induced cell cycle arrest in G₁ (Fig. 4D). For MG-63 cells with CENPF depletion, 57.72% cells were in G₁ compared with 40.67% in sh-control cells (P<0.05; Fig. 4D). For U-2 OS, G₁ cells increased 19.51% after knocking down CENPF (P<0.05; Fig. 4D).

**Depletion of CENPF inhibits osteosarcoma tumor growth in vivo.** To determine whether CENPF inhibited tumor growth in vivo, control or CENPF stably-depleted MG-63 cells were implanted into nude-BALB/c mice, and the tumor volume was quantified every 3 days. The tumor growth curve revealed that xenografts with CENPF depletion were significantly smaller compared with the control xenografts (Fig. 5A). Immunoblot assays showed that xenografts derived from CENPF stably-depleted tumor tissues had a lower expression level of CENPF compared with control tissues (Fig. 5B). Therefore, these data revealed that depletion of CENPF inhibited the growth osteosarcoma tumors in vivo.

**Discussion**

As a component of the centromere-kinetochore complex, CENPF has been reported to play a notable role in carcinogenesis and affects the progression of a number of human tumors, such as breast cancer, pancreatic carcinoma and prostate cancer (1,14-18). Previous studies have reported that CENPF is localized in the nucleus of prostate cancer cells, and its expression is associated with the poor prognosis of patients with prostate cancer (19-21). By analyzing the data in TCGA database and the protein levels of CENPF in patient samples, the present study found that the mRNA and protein expression levels of CENPF were both significantly upregulated in osteosarcoma tissues. Patients with high CENPF expression levels had poorer OS and DFS rates. Similarly, Li et al (22) analyzed four mRNA microarrays from the Gene Expression Omnibus database and found that CENPF is overexpressed in lung cancer and associated with poor prognosis. CENPF has already been reported to be overexpressed in the early-stages of hepatocellular carcinoma (HCC) and as a tumor-associated antigen (23,24). Previous studies have also confirmed the
Figure 4. Depletion of CENPF inhibits osteosarcoma cell proliferation by inducing cell cycle arrest and apoptosis. (A and B) Colony formation assay and Cell Counting Kit-8 assay were performed to detect cell proliferation in CENPF-depleted cells and control cells. (C) Apoptosis was detected with the staining of Annexin V-FITC/PI by flow cytometry. (D) Cell cycle assay was performed, and cells were stained with PI and analyzed by using flow cytometry. *P<0.05 compared with sh-control. CENPF, centromere protein F; PI, propidium iodide; sh-, short hairpin.
diagnostic value of CENPF in early HCC and CENPF was upregulated in HCC and was associated with poor outcome (25‑28).

In the present study, the IHC data of osteosarcoma samples demonstrated that CENPF upregulated in 82% of tumors, and was associated with T stage and intraglandular dissemination. In a previous study on prostate cancer, 8,066 out of 9,055 (89%) stains were found to be CENPF-positive, whereas normal prostate tissues showed absent or weak CENPF staining (29). In prostate cancer, high expression levels of CENPF are associated with indicators of advanced pathological stage, such as high Gleason grade and lymph node metastasis (19‑21,29). Similarly, a previous study revealed that high CENPF expression levels are associated with a high Ki67-labeling index, showing that CENPF is associated with tumor cell proliferation (29). In line with the findings of the current study, CENPF is also upregulated in other human tumors, including breast cancer, esophageal cancer and nasopharyngeal cancer (8,30‑35).

To further explore the effect of CENPF on osteosarcoma cells, the present study performed cell cloning using cells transfected with CENPF shRNA lentivirus, combined with flow cytometry and apoptosis analysis. CENPF was found to affect the cell cycle and apoptotic pathway and promoted the proliferation of tumor cells. The current study was consistent with previous reports demonstrating that CENPF promoted tumor cell proliferation. For example, Laoukili et al (36) identified CENPF as a direct target gene of forkhead box protein M1, which is a notable cell cycle regulator which activates MAPK and PI3K/AKT signaling pathways. Sun et al (10) reported that overexpression of CENPF is associated with P53 signaling pathways. Notably, the AKT/mTOR signaling pathway is inhibited when CENPF protein expression is depleted via transfection in breast cancer cells, and depletion of CENPF inhibits the synthesis and phosphorylation of AKT/mTOR pathway components in these cells, such as phosphorylated (p)-AKT and p-mTOR (10).

However, the limitation of the current study is that it is a retrospective study and the expression levels of CENPF was analyzed in a limited number of osteosarcoma specimens. Additionally, the present study did not involve detailed research into the mechanism of CENPF. Therefore, for clinical application, such as inhibited tumor by targeting CENPF using antisense oligonucleotide, a larger number of samples and in-depth exploration are needed.

In conclusion, the data from the present study indicated that CENPF was an independent negative prognostic factor in patients with osteosarcoma. CENPF promoted cell proliferation by the regulation of cell cycle and apoptosis. These data may therefore provide a possible biomarker and prognostic prediction factor of osteosarcoma.

Figure 5. Decreased expression of CENPF inhibits tumor growth of osteosarcoma cells in mice. (A) Tumor volume was calculated every 3 days, and the tumor growth curve was drawn after the mice were sacrificed, and the representative tumor images were plotted. (B) Protein expression levels of CENPF were detected through immunoblotting in control or CENPF stably-depleted tumors. *P<0.05 compared with sh-control. CENPF, centromere protein F; sh-, short hairpin.
Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
PAZ, ZXY and XW performed the experiments. PAZ and ZWT participated in the project design and coordination of the experiments and helped to draft the manuscript. PAZ and ZWT confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
All human experiments were approved by The Human Ethics Committee of Jiangxi Cancer Hospital and all procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All animal experiments were approved by The Laboratory Animal Ethics Committee of Jiangxi Cancer Hospital (Jiangxi, China; grant no. SYXK 2019-0522).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Caudill JS and Arndt CA: Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev 18: 62-78, 2007.
2. Sisson HA: The WHO classification of bone tumors. Recent Results Cancer Res 54: 104-108, 1976.
3. Mason NJ: Comparative immunology and immunotherapy of canine osteosarcoma. Adv Exp Med Biol 1258: 199-221, 2020.
4. von Eisenhart-Rothe R, Toepfer A, Salzmann M, Schauwecker J, Gollwitzer H and Rechl H: Primary malignant bone tumors. Orthopade 34: 1121-1142, 2011 (In German).
5. Jaffe N, Carrasco H, Raymond K, Ayala A and Eftekhar H: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95: 2202-2210, 2002.
6. Berto A, Yu J, Morchoisne-Bolhy S, Bertipaglia C, Vallee R, Dumont J, Ochsenbein F, Guerrios R and Doye V: Disentangling the molecular determinants for Cenp-F localization to nuclear pores and kinetochore. EMBO Rep 19: e44742, 2018.
7. Shahid M, Lee MY, Pipiani H, Andres AM, Zhou B, Yeon A, Kim M, Kim HL, and Kim J: Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. Cell Cycle 17: 2802-2818, 2018.
8. Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G and Landberg G: Immunohistochemical analysis of the proliferation-associated nuclear antigen CENP-F in non-Hodgkin’s lymphoma. Mod Pathol 12: 69-74, 1999.
9. Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, Gong S and Zhe Y: Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine 40: 382-393, 2019.
10. Sun J, Huang J, Lan J, Zhou K, Gao Y, Song Z, Deng Y, Liu L, Dong Y and Liu X: Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int 19: 264, 2019.
11. Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 25, 402-408, 2001.
13. Sun B, Lin G, Ji D, Li S, Chi G and Jin X: Dysfunction of sister chromatids separation promotes progression of hepatocellular carcinoma according to analysis of gene expression profiling. Front Physiol 9: 1019, 2018.
14. Alghamdi M, Alkhamsi WH, Bashiri FA, Jamjoom D, Al-Madjedih G, Tahiri A and Abdouleh M: Expanding the phenotype and the genotype of Stromme syndrome: A novel variant of the CENPF gene and literature review. Eur J Med Genet 63: 103844, 2020.
15. Chen EB, Qin X, Peng K, Li Q, Tang C, Wei YC, Yu S, Gan L and Liu TS: HnRNP-CC/NEF/CENPF axis contributes to gastric cancer proliferation and metastasis. Aging (Albany NY) 11: 7473-7491, 2019.
16. Li R, Wang X, Zhao X, Zhang X, Chen H, Ma Y and Liu Y: Centromere protein F and forkhead box M1 correlation with prognosis of non-small cell lung cancer. Oncol Lett 19: 1368-1374, 2020.
17. Liu ZK, Zhang RY, Yong YL, Zhang ZY, Li C, Chen ZN and Bian H: Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis. Peer J 7: e7436, 2019.
18. Mahmoud AD, Ballantyne MD, Mischinovin V, Pinel K, Hung J, Scanlon JP, Iyinikkel J, Kaczynski J, Tavares AS, Bradshaw AC, et al: The human-specific and smooth muscle cell-enriched IncRNA SMILR promotes proliferation by regulating mitotic CENPF mRNA and drives cells-cycle progression which can be targeted to limit vascular remodeling. Circ Res 125: 535-551, 2019.
19. Lokody I: Signalling: FOXM1 and CENPF: Co-pilots driving prostate cancer. Nat Rev Cancer 14: 450-451, 2014.
20. Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, Tsai SY and Tsai MJ: Dysregulation of miRNAs-COUPTF1-FIOLX1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun 7: 11418, 2016.
21. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martín M, Zheng T, Eastham JA, Gopalan A, Pentà KJ, Shen MM, et al: Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25: 638-651, 2014.
22. Li Z, Sang M, Tian Z, Liu Z, Lv J, Zhang F and Shan B: Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis. Oncol Lett 18: 4429-4440, 2019.
23. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK and Tan EM: De novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 125: 3-9, 2001.
24. Hong Y, Long J, Li H, Chen S, Liu Q, Zhang B, He X, Wang Y, Li H, Li Y, et al: An analysis of immunoreactive signatures in early stage hepatocellular carcinoma. EBioMedicine 2: 438-446, 2015.
25. Li S, Li X, Xu A, Zhang B, He X, Chen H and Huang J: Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma. Mol Med Rep 17: 4720-4728, 2018.
26. Wan Z, Zhang X, Luo Y and Zhao B: Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses. Genet Test Mol Biomarkers 23: 766-777, 2019.
27. Yang X, Miao BS, Wei CY, Dong RZ, Gao PT, Zhang XY, Lu JC, Gao C, Wang XY, Sun HC, et al: Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. Cancer Sci 110: 2133-2144, 2019.

28. Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, et al: Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One 7: e43223, 2012.

29. Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, et al: Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Manag Res 10: 5491-5504, 2018.

30. O’Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 120: 1434-1443, 2007.

31. Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD and Wu CL: Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer. Int J Mol Med 35: 966-972, 2015.

32. Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, et al: Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer 9: 237, 2010.

33. Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, Li Y, Yuan YF, Ma S and Guan XY: Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun 436: 711-718, 2013.

34. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, et al: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53: 235-240, 2004.

35. Mi YJ, Gao J, Xie JD, Cao JY, Cui SX, Gao HJ, Yao SP, Liu T, Zhang YY, Guo CH, et al: Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dis Esophagus 26: 636-643, 2013.

36. Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136, 2005.